Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1548
Title: Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome.
Epworth Authors: Prince, Miles
Other Authors: Querfeld, C.
Keywords: Novel Systemic Therapies
Advanced-Stage Disease
Early-Stage Disease
Skin-Directed Therapies
Systemic Chemotherapy
Biological Agents
Interferon Alfa
Bexarotene
Histone Deacetylase Inhibitors
Brentuximab Vedotin
Mogamulizumab
Extracorporeal Photopheresis
Sézary Syndrome
Allogeneic Transplantation
Novel Agents
Monoclonal Antibody IPH4102
Duvelisib
Denileukin Diftitox
Patient Factors
Efficacy
Toxicity
Biological Agents
Lymphoma
Cutaneous
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Sep-2018
Publisher: Bailliere Tindall Ltd
Citation: Best Pract Res Clin Haematol. 2018 Sep;31(3):322-335.
Abstract: Novel systemic therapies are generally prescribed to patients with advanced-stage disease or those with early-stage disease refractory to skin-directed therapies. In general, systemic chemotherapy should be reserved for patients who fail to respond to biological agents. Such biological agents include interferon alfa, bexarotene, histone deacetylase inhibitors (vorinostat, romidepsin), brentuximab vedotin and mogamulizumab. Extracorporeal photopheresis is particularly effective for patients with Sézary Syndrome. Allogeneic transplantation is becoming increasing used for younger patients. Novel agents in advanced development include the monoclonal antibody IPH4102,duvelisib,and the new modified formulation of denileukin diftitox. The choice of agents for patients is typically a balance of patient factors (age, co-morbidities, geographic location), relative efficacy and toxicity.
URI: http://hdl.handle.net/11434/1548
DOI: 10.1016/j.beha.2018.07.007
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/30213403
ISSN: 1521-6926
1532-1924
Journal Title: Best Practice & Research Clinical Haematology
Type: Journal Article
Affiliated Organisations: Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia
City of Hope National Medical Center, Beckman Research Institute, California, USA
Type of Clinical Study or Trial: Review
Appears in Collections:Cancer Services

Files in This Item:
There are no files associated with this item.


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.